News

Ballestar lab 2022

Researchers find epigenetic alterations in the immune system behind severe Covid-19

Monocytes from severe covid-19 patients show an altered epigenetic status, according to results by the Epigenetic and Immune Disease group of the Josep Carreras Leukaemia Research Institute. The alterations found in these cells, key in promoting inflammation, can explain features of the aberrant immune response against Sars-Cov-2 infection, such as impaired communication with other immune cells and maturation defects. This comprehensive analysis of monocyte’s epigenetics under severe covid-19, the first of its kind, stresses the importance of these cells in modulating the immune response.

Read more
Eduard Porta Entrevista

Eduard Porta: "The future of Artificial Intelligence in biomedicine is bright"

Dr. Eduard Porta, leader of the Cancer Immunogenomics group at the Josep Carreras Leukaemia Research Institute, has participated in a community initiative to put into context the value of AlphaFold2 predictions, an algorithm created by Deep Mind, the Google's specialized artificial intelligence company, capable of determining the three-dimensional structure of all known human proteins. Their conclusions have recently been published in the specialized journal Nature Structural Biology.

Read more
Unoentrecienmil 2022

Unoentrecienmil awards a project for the development of an immunotherapy against one of the pediatric leukemias with the worst prognosis

The Unoentrecienmil Foundation, which promotes research projects for the complete cure of childhood leukemia, today awarded its 9th Annual Research Grant to Dr. Clara Bueno of the Josep Carreras Leukaemia Research Institute. For two years, the Doctor will carry out her work to develop new therapeutic strategies, some based on immunotherapy, against the NG2 antigen, related to relapses of B-cell Acute Lymphoblastic Leukemia with alterations in the MLL gene, and thus improve the survival rate of these patients, now at 35%.

Read more
IJC Building white wall

The Josep Carreras Leukemia Research Institute stabilizes 21 structural positions, becoming one of the fastest growing research centers in Catalonia

The Official Journal of the Generalitat of Catalonia has just published the resolution that stabilizes 21 places in the administration units and common services of the Josep Carreras Leukaemia Research Institute. With this stabilization, the Research Institute adopts an indefinite hiring scheme, as commanded by the latest Spanish labor reform.

Read more
Ballestar lab 2022

Vitamin C may hold the key to improve efficacy of dendritic cell-derived anticancer cell therapies

Researchers from the Epigenetics and Immune Disease Lab at the Josep Carreras Leukaemia Research Institute has recently shown that vitamin C improves the immunogenic properties of dendritic cells, in vitro. Results recently made public show that treating the cells with vitamin C leads to a more consistent activation of genes involved in the immune response, mainly through DNA demethylation, a kind of epigenetic reprogramming. This discovery may be useful to generate more potent dendritic cell-based therapies in the future.

Read more
CarrerasLeaders

CarrerasLeaders: Postdoctoral Program Empowering Future Leaders to Fight Blood Cancers

CarrerasLeaders is a new innovative and international postdoctoral program, designed by the Josep Carreras Leukaemia Research Institute (IJC), which receives funding from the European Commission Horizon Europe Marie Curie Skodowska COFUND Program (GA No. 101081347) and counts with the collaboration of the Josep Carreras International Foundation and the scientific coordination of Dr Buschbeck.

Read more